# The Potential Impact of Interruptions to HIV Services: A Modelling Case Study for South Africa

Britta Jewell, Jennifer Smith, Timothy Hallett

MRC Centre for Global Infectious Disease Analysis Department of Infectious Disease Epidemiology Imperial College London

b.jewell@imperial.ac.uk; jennifer.smith@imperial.ac.uk; timothy.hallett@imperial.ac.uk

# **Summary**

The numbers of deaths caused by HIV could increase substantially if the COVID-19 epidemic leads to interruptions in the availability of HIV services. We compare publicly available scenarios for COVID-19 mortality with predicted additional HIV-related mortality based on assumptions about possible interruptions in HIV programs. An interruption in the supply of ART for 40% of those on ART for 3 months could cause a number of deaths on the same order of magnitude as the number that are anticipated to be saved from COVID-19 through social distancing measures. In contrast, if the disruption can be managed such that the supply and usage of ART is maintained, the increase in AIDS deaths would be limited to 1% over five years, although this could still be accompanied by substantial increases in new HIV infections if there are reductions in VMMC, oral PrEP use, and condom availability.

## **Background**

In addition to the direct health impact of the COVID-19 epidemic, there may also be a detrimental impact on service provision for other health conditions due to increasing demands on overall health service capacity, interruptions to supply of medicines, or funding shortages. Here we examine the impact of potential hypothetical disruption to HIV services in South Africa. Interruptions to different elements of the HIV treatment and prevention cascades have differential impacts on the resulting loss of health and it will be useful for decision-makers to understand the relative impact of different reductions in service in order to inform planning for service continuity during the COVID-19 epidemic.

## Methods

We hypothesised three patterns of disruption to HIV services in South Africa that might occur during the COVID-19 epidemic, described below and summarised in Table 1. Each scenario is cumulative in the sense that it incorporates the changes described in all less severe scenarios. In the first instance, we assume the disruption begins in mid-April 2020 and lasts for 3 months, and that thereafter normal service resumes for all programs.

## 1. Managed pause (least severe):

In this scenario, the expansion of services planned for this time is paused but all services are maintained at their current levels. This might occur, for instance, if there is very little actual disruption to the HIV programs, but opportunities to expand are not available due to it being impractical to run outreach services and persons not yet engaged with care postponing testing.

## 2. Managed disruption:

In this scenario, substantial pressure on the health system and social distancing measures combine to disrupt services, but these are sufficiently well managed that their worst impacts are mitigated, and the supply of ART is maintained. In addition to the effects of the first scenario ('Managed pause') there is also a reduction in condom use, as might be caused by reduced supply of condoms and less opportunity to acquire them, and decreased viral suppression, as might be caused by a combination of persons being less inclined or able to present for routine viral load testing, viral load testing not being so widely available (due to increased usage of laboratory equipment), and short-term fluctuations in the supply of ART drugs.

### *3. Interruption of supply* (most severe):

In this scenario, extreme pressure on the health system and/or strict interventions and stressed supply chains domestically and internationally combine to interrupt the supply of key medicines, with the result that a fraction of people living with HIV (PLHIV) on ART are forced off ART.

We used an established deterministic mathematical model of the HIV epidemic in South Africa to quantify the impact of these disruptions over the five-year period, 2020-2024.[1, 2] The number of 'excess' outcomes (deaths and life-years lost) that are attributed to these disruptions are computed in reference to a model projection in which no interruptions occur and the coverage of programs expands in the manner that would have otherwise been anticipated.

We compared the effect on HIV programmes to the anticipated direct effects from a COVID-19 epidemic in South Africa (Table 2).[3]

Scenario	Assumed Impact on HIV Programs
1. Managed pause	-No new ART enrolments
(least severe)	-No new VMMC
	-(No new PrEP enrolments*)
2. Managed disruption	-No new ART enrolments
	-No new VMMC
	-(No PrEP prescription enrolment or prescription refills*)
	-Viral suppression decreases by 10%
	-Condom use decreases by 50%
3. Interruption of supply	-No new ART enrolments
(most severe)	-No new VMMC
	-(No PrEP enrolment or prescription refills*)
	-Viral suppression decreases by 10% across individuals on ART
	-Condom use decreases by 50%
	-40% of individuals on ART go off of ART for duration of interruption, assuming a 0.60% risk of death per month during the interruption**

**Table 1:** Scenarios characterising disruption to HIV services due to the COVID-19 epidemic.

<sup>\*\*</sup>We optimistically assume that if individuals have stopped ART use due to the COVID-19 disruption, they immediately return to ART once supply resumes and their long-term prognosis on ART is not affected by the interruption in ART usage.

1.	Unmitigated epidemic	No action is taken								
	(most severe)									
2.	Social distancing	Population-level social distancing – the maximum reduction in the final scale of the epidemic that can be achieved through a uniform reduction in the rate at which individuals contact one another, short of complete suppression. For South Africa, this equates to 37-48% reduction in social contacts.								
3.	Enhanced social distancing	As above but with individuals aged 70 years old and above								
	(least severe)	reducing their social contact rates by 60%.								
Tal	Table 2: Public health responses to the COVID-19 epidemic (from [3]).									

Results are most sensitive to the risk of dying for PLHIV who have had their ART supply interrupted. This quantity is not well known or understood. For the main analysis, we assume an average monthly risk of death of 0.60% for this group. We conducted a sensitivity analysis using three different values for this value (Table 3). We also note that the monthly risk of death is likely to increase over time as individuals accrue time off of ART; however, this is not represented in the model.

Important limitations to note include: (i) we do not model any interaction between HIV and COVID-19 infection – that is, PLHIV are not assumed to be more or less likely to acquire or die from COVID-19; (ii) the effect of disruption on the risk of mother-to-child transmission is not included in this model; (iii) the effects of any social distancing on risk behaviours and new partner acquisition is not included; (iv) possible increases in drug resistance due to ART regimens being disrupted are not included but these could also contribute to excess HIV deaths in the longer term.


<sup>\*</sup>PrEP coverage is assumed to be small and does not affect directly results presented here.

	Monthly mortality risk	Proportion that would die after one	Justification
		year	
Lower bound	0.26%	3%	The SMART trial found a 3% risk at 12 months of either death of an opportunistic infection for those with interrupted ART.[4]
Medium	0.60%	7%	This implies a mean survival of 14 years which is approximately the survival time for HIV-positive persons who have never been on ART.[5]
Upper bound	1.04%	12%	This is the hypothetical worst-case scenario in which the many persons deteriorate more rapidly.

**Table 3**: Alternative assumptions used for the risk of death experienced by those PLHIV whose ART supply is interrupted.

#### Results


Figure 1 shows the projected number of COVID-19 deaths for the three intervention scenarios from [3], together with the projections for excess HIV-related deaths in South Africa over time for the three service disruption scenarios. The excess HIV-related deaths are spread over the five-year time period, in contrast to the direct COVID-19 deaths, which all occur in 2020-2021.



**Figure 1**: Projected direct and indirect deaths over time, under different assumptions about the COVID-19 epidemic and the impact on HIV services (Table 1), for three months of service interruption. Confidence intervals represent uncertainty in the monthly mortality risk for individuals with interrupted ART, ranging from 0.26%-1.04% per month.

The numbers of additional HIV-related deaths in the less severe scenarios ('Managed pause' and 'Managed disruption') are small (less than 1%) but could nevertheless lead to a significant increase in new HIV infections (Figure 2), setting back HIV control efforts. For the most severe 'Interruption of supply' scenario, 23,000 excess HIV-related deaths in the first year represent a substantial increase on the 71,000 HIV-related deaths estimated in South Africa in 2018.[6] Over five years, the total number of excess deaths caused by the disruptions (38,000) is smaller than those that would be caused by the COVID-19 epidemic itself, but of the same order of magnitude as the reductions in deaths that could be caused by the proposed COVID-19 epidemic mitigation interventions (i.e., social distancing for the whole population (73,000 fewer deaths), or social distancing with enhanced social distancing for the elderly (a further 45,000 fewer deaths)). These excess HIV-related deaths are initially attributed primarily to the increased mortality risk for people stopping ART use, but over five years an increasing proportion are also due to others not having achieved a timely ART initiation during the interruption.

We also examined scenarios in which the duration of disruptions and the proportion of PLHIV on ART who are affected were varied and alternative assumptions were made for the mortality risk for persons whose ART is interrupted (Figure 3). Under the lowest mortality assumption, for most scenarios there are fewer additional HIV-related deaths than COVID-19 deaths and fewer HIV-related deaths compared to those that could be saved by the interventions to prevent COVID-19 epidemic spread. However, it is worth noting that under some very severe (and unlikely) circumstances of wide-spread and long interruptions of ART, the number of additional HIV-related deaths could be much greater than our default assumptions suggest.



**Figure 2**: Excess HIV infections in South Africa over 5 years for three scenarios (managed pause = blue bars, managed disruption = orange bars, interruption of supply = yellow bars) for a three month interruption.

Figure 3: The number of excess cumulative HIV deaths in South Africa over 5 years by the duration of interruption (months) and the proportion of people living with HIV (PLHIV) who are on ART affected by the interruption. Three scenarios are presented for mortality risk per month for PLHIV who have ceased ART due to the interruption: (A) 0.26%, (B) 0.60%, and (C) 1.04%. Colour gradients correspond to deaths greater than the lower number of deaths expected with enhanced social distancing for a COVID-19 epidemic in Africa with  $R_0$ =2.4. Light pink corresponds to  $\geq 1$  times the number of COVID-19 deaths with the darkest colour corresponding to  $\geq 4$  times the number of COVID-19 deaths.

(A) 0.26% mortality risk per month for PLHIV who have dropped off of ART

		Proportion of PLHIV on ART affected										
		0%	10%	20%	30%	40%	50%	60%	70%	80%	90%	100%
<b>∞</b>	0	0	0	0	0	0	0	0	0	0	0	0
iths)	1	0	3,117	4,330	5,577	6,860	8,182	9,548	10,964	12,439	13,982	15,603
و	2	0	5,548	7,627	9,752	11,922	14,138	16,407	18,735	21,133	23,610	26,180
ے	3	0	7,824	10,678	13,587	16,542	19,543	22,596	25,708	28,886	32,143	35,491
Suc	4	0	10,134	13,762	17,451	21,187	24,970	28,803	32,694	36,651	40,683	44,805
ptio	5	0	12,501	16,899	21,366	25,880	30,440	35,051	39,718	44,448	49,253	54,144
5	6	0	14,945	20,110	25,350	30,639	35,975	41,359	46,798	52,299	57,872	63,530
Ę	7	0	17,510	23,440	29,451	35,511	41,617	47,771	53,979	60,246	66,584	73,004
of E	8	0	20,191	26,884	33,663	40,492	47,366	54,287	61,260	68,292	75,391	82,570
	9	0	23,000	30,454	37,999	45,595	53,235	60,921	68,657	76,451	84,309	92,245
ation	10	0	25,948	34,162	42,472	50,833	59,237	67,686	76,183	84,736	93,352	102,042
5	11	0	29,043	38,017	47,090	56,214	65,381	74,591	83,848	93,159	102,530	111,974
۵	12	0	32,295	42,027	51,863	61,749	71,678	81,648	91,664	101,730	111,856	122,052

(B) 0.60% mortality risk per month for PLHIV who have dropped off of ART

	-		Proportion of PLHIV on ART affected										
		0%	10%	20%	30%	40%	50%	60%	70%	80%	90%	100%	
<b>∞</b>	0	0	0	0	0	0	0	0	0	0	0	0	
nths)	1	0	5,023	8,494	12,048	15,688	19,423	23,266	27,233	31,341	35,616	40,084	
ρ	2	0	8,943	15,005	21,183	27,468	33,867	40,394	47,067	53,908	60,944	68,208	
L)	3	0	12,599	21,021	29,579	38,247	47,030	55,939	64,991	74,207	83,614	93,243	
Suc	4	0	16,287	27,054	37,975	49,011	60,161	71,435	82,849	94,424	106,184	118,161	
ptio	5	0	20,027	33,124	46,393	59,780	73,281	86,904	100,664	114,580	128,678	142,987	
1 5	6	0	23,840	39,251	54,853	70,575	86,410	102,366	118,456	134,698	151,116	167,741	
inte	7	0	27,769	45,479	63,393	81,431	99,582	117,850	136,250	154,797	173,517	192,436	
of ii	8	0	31,810	51,804	72,017	92,355	112,806	133,372	154,065	174,903	195,908	217,108	
_	9	0	35,976	58,240	80,737	103,362	126,097	148,945	171,918	195,032	218,307	241,771	
ation	10	0	40,277	64,798	89,565	114,461	139,467	164,584	189,821	215,195	240,726	266,441	
j	11	0	44,722	71,488	98,511	125,665	152,927	180,298	207,786	235,406	263,179	291,129	
٥	12	0	49,319	78,317	107,584	136,982	166,487	196,097	225,822	255,675	285,675	315,847	

(C) 1.04% mortality risk per month for PLHIV who have dropped off of ART

			Proportion of PLHIV on ART affected										
		0%	10%	20%	30%	40%	50%	60%	70%	80%	90%	100%	
<u>@</u>	0	0	0	0	0	0	0	0	0	0	0	0	
nths)	1	0	7,805	14,204	20,716	27,347	34,112	41,029	48,120	55,412	62,937	70,737	
JO.	2	0	13,926	25,372	36,978	48,733	60,649	72,744	85,044	97,581	110,392	123,525	
<u> </u>	3	0	19,618	35,732	52,037	68,497	85,117	101,914	118,911	136,139	153,634	171,442	
Suc	4	0	25,314	46,043	66,992	88,101	109,370	130,812	152,451	174,314	196,437	218,864	
ptio	5	0	31,035	56,326	81,865	107,569	133,431	159,465	185,689	212,132	238,828	265,819	
זי	6	0	36,802	66,603	96,678	126,922	157,324	187,894	218,650	249,618	280,832	312,333	
nte	7	0	42,653	76,900	111,445	146,164	181,039	216,078	251,299	286,726	322,392	358,335	
of ir	8	0	48,590	87,233	126,197	165,337	204,633	244,089	283,722	323,556	363,620	403,954	
-	9	0	54,627	97,616	140,947	184,458	228,123	271,944	315,938	360,126	404,538	449,211	
atio	10	0	60,774	108,061	155,709	203,540	251,523	299,659	347,962	396,454	445,163	494,124	
<u> </u>	11	0	67,040	118,577	170,493	222,594	274,845	327,245	379,808	432,554	485,509	538,708	
٥	12	0	73,434	129,173	185,309	241,630	298,100	354,716	411,489	468,439	525,591	582,979	

#### **Conclusions**

Maintaining ART treatment during any health system disruptions during the COVID-19 epidemic is the overriding priority for HIV programs. A wide-spread and long-lasting interruption to ART supply could cause additional deaths on the same order of magnitude as those which could be saved by interventions to mitigate the COVID-19 epidemic itself. Some of the negative impacts of service disruption could be minimised by policy changes that are beneficial to HIV programs in the long-term – for example, adaptations to ART delivery such as multi-month ART scripting are now recommended for consideration in appropriate circumstances by the WHO and PEPFAR.[7, 8] However, if an interruption to ART supplies does occur, it may also take programs longer than assumed here to return to status quo, with further adverse effects expected among individuals who experience long-term ART disruptions.

Some short-term changes to programs, such as scaling back new VMMC and reduced use of condoms, may be less impactful in terms of the excess number of deaths in the medium-term, but we note that new HIV infections would increase and could have further long-term ramifications not represented in the five-year time horizon. The analysis presented here is for South Africa, but it is anticipated that the overall direction of the results will be similar for many countries in sub-Saharan Africa with large HIV epidemics.

The assumptions made are not predictions of the future, but hypothetical scenarios designed to allow this analysis to highlight the importance of maintaining different services during the COVID-19 epidemic. The model itself has many limitations (noted above). The major uncertainties in this analysis can be classified into four groups: (1) uncertainty about the scale of the COVID-19 epidemic (how far and fast will it spread and with what chance of death for those infected); (2) uncertainty into the extent to which HIV programs will actually be disrupted by the COVID-19 epidemic and the response to it; (3) uncertainty about changes to patterns of sexual risk behaviour in response to the epidemic; and (4) uncertainty about the mortality risk of those persons on ART who may suffer an interruption in the supply of drug.

We have not assumed any interaction between HIV or ART status and COVID-19 infection in this analysis. This may need to be revised as more information becomes available, and may influence outcomes particularly in areas with large numbers of PLHIV who are not virally suppressed.

We have also not assumed any changes in sexual risk behaviour. A reduction in sexual contact rates could reduce incidence rates and hence new infections but would have a limited impact on the number of deaths over five years. Furthermore, interruptions to condom supplies could counteract any incidence decline. Reductions in condom availability could also have differential impacts on new HIV infections among different populations; for example, female sex workers might be at higher excess risk than women in stable partnerships. Ensuring support for community prevention programs during the COVID-19 epidemic will help to mitigate these potential effects.

The range of mortality effects due to ART disruption will depend on the health and immune status of the person, the drugs they are using and their treatment history, as well as any steps that are taken to prolong supply (alternate day dosing, for example). For this reason, we have repeated the analysis for a wide range of values, but even within this, it may be that the effect has been over or underestimated. Ultimately, ensuring the ART supply for individuals currently on treatment would minimise excess mortality among PLHIV in South Africa, and should be a key policy priority.

## References

- 1. Cremin, I., et al., *The new role of antiretrovirals in combination HIV prevention: a mathematical modelling analysis.* AIDS, 2013. **27**(3): p. 447-458.
- 2. Smith, J.A., et al., *Maximising HIV prevention by balancing the opportunities of today with the promises of tomorrow: a modelling study.* The Lancet HIV, 2016. **3**(7): p. e289-e296.
- 3. Walker, P.G., et al., *The Global Impact of COVID-19 and Strategies for Mitigation and Suppression*. 2020, Imperial College London.
- 4. The Strategies for Management of Antiretroviral Therapy (SMART) Study Group, *CD4+ Count—Guided Interruption of Antiretroviral Treatment*. New England Journal of Medicine, 2006. **355**(22): p. 2283-2296.
- 5. Todd, J., et al., *Time from HIV seroconversion to death: a collaborative analysis of eight studies in six low and middle-income countries before highly active antiretroviral therapy.* AIDS, 2007. **21**(Suppl 6): p. S55-63.
- 6. UNAIDS. AIDSInfo. 2020 [cited 2020 22nd April]; Available from: <a href="https://aidsinfo.unaids.org">https://aidsinfo.unaids.org</a>.
- 7. PEPFAR. PEPFAR Technical Guidance in Context of COVID-19 Pandemic. April 8, 2020 Updates. 2020 [cited 2020 22nd April]; Available from: <a href="https://www.state.gov/wp-content/uploads/2020/04/04.08.2020">https://www.state.gov/wp-content/uploads/2020/04/04.08.2020</a> PEPFAR Technical Guidance During COVID.pdf.
- 8. World Health Organisation. *Q&A on COVID-19, HIV and antiretrovirals*. 2020 [cited 2020 22nd April]; Available from: <a href="https://www.who.int/news-room/q-a-detail/q-a-on-covid-19-hiv-and-antiretrovirals">https://www.who.int/news-room/q-a-detail/q-a-on-covid-19-hiv-and-antiretrovirals</a>.